Literature DB >> 10543765

Differential modulatory effects of clarithromycin on the production of cytokines by a tumor.

K Sassa1, Y Mizushima, M Kobayashi.   

Abstract

In vitro treatment with clarithromycin inhibited the expression of the matrix metalloproteinase-9, transforming growth factor beta, and tumor necrosis factor alpha genes in 13762NF rat mammary adenocarcinoma cells. Transient enhancement, rather than inhibition, was observed for the interleukin-6 gene, and no significant change was observed for the tissue inhibitor of metalloproteinase-2 gene. Such an effect was not observed for cefotiam or gentamicin.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10543765      PMCID： PMC89561     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Significant survival benefit to patients with advanced non-small-cell lung cancer from treatment with clarithromycin.

Authors:  K Mikasa; M Sawaki; E Kita; K Hamada; S Teramoto; M Sakamoto; K Maeda; M Konishi; N Narita
Journal:  Chemotherapy       Date:  1997 Jul-Aug       Impact factor: 2.544

2.  Therapeutic effect of clarithromycin on a transplanted tumor in rats.

Authors:  K Sassa; Y Mizushima; T Fujishita; R Oosaki; M Kobayashi
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

Review 3.  The biology of interleukin-6.

Authors:  T Kishimoto
Journal:  Blood       Date:  1989-07       Impact factor: 22.113

4.  Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates.

Authors:  C Heussen; E B Dowdle
Journal:  Anal Biochem       Date:  1980-02       Impact factor: 3.365

5.  Enhanced interleukin production after long-term administration of erythromycin stearate.

Authors:  E Kita; M Sawaki; F Nishikawa; K Mikasa; Y Yagyu; S Takeuchi; K Yasui; N Narita; S Kashiba
Journal:  Pharmacology       Date:  1990       Impact factor: 2.547

6.  Antitumor effect of erythromycin in mice.

Authors:  K Hamada; E Kita; M Sawaki; K Mikasa; N Narita
Journal:  Chemotherapy       Date:  1995 Jan-Feb       Impact factor: 2.544

7.  Differential modulation of cytokine production by macrolides: interleukin-6 production is increased by spiramycin and erythromycin.

Authors:  S Bailly; J J Pocidalo; M Fay; M A Gougerot-Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

8.  Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in vitro.

Authors:  K Morikawa; F Oseko; S Morikawa; K Iwamoto
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

Review 9.  Tumor necrosis factor and cachexia: a current perspective.

Authors:  N J Espat; E M Copeland; L L Moldawer
Journal:  Surg Oncol       Date:  1994-10       Impact factor: 3.279

Review 10.  Some recent advances in the chemistry and biology of transforming growth factor-beta.

Authors:  M B Sporn; A B Roberts; L M Wakefield; B de Crombrugghe
Journal:  J Cell Biol       Date:  1987-09       Impact factor: 10.539
View more
  6 in total

Review 1.  Immuno-modulation and anti-inflammatory benefits of antibiotics: the example of tilmicosin.

Authors:  André G Buret
Journal:  Can J Vet Res       Date:  2010-01       Impact factor: 1.310

2.  Macrolide antibiotics differentially influence human HepG2 cytotoxicity and modulate intrinsic/extrinsic apoptotic pathways in rat hepatocellular carcinoma model.

Authors:  Nagwa I Abdel-Hamid; Mona F El-Azab; Yasser M Moustafa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-01-09       Impact factor: 3.000

3.  In vitro effects of ciprofloxacin and roxithromycin on apoptosis of jurkat T lymphocytes.

Authors:  Yong-Taek Jun; Hee-Jung Kim; Min-Jin Song; Ji-Hyang Lim; Dong-Gun Lee; Kyung-Ja Han; Su-Mi Choi; Jin-Hong Yoo; Wan-Shik Shin; Jung-Hyun Choi
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

4.  Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent.

Authors:  An Mt Van Nuffel; Vidula Sukhatme; Pan Pantziarka; Lydie Meheus; Vikas P Sukhatme; Gauthier Bouche
Journal:  Ecancermedicalscience       Date:  2015-02-24

5.  Complete Remission of Methotrexate-Related Epstein-Barr-Virus-Associated Hodgkin-Like Lymphoma following Withdrawal of MTX Coupled with Clarithromycin Administration.

Authors:  Nobuo Takemori; Hiroyuki Kaneko; Masaya Nakamura; Masaru Kojima
Journal:  Case Rep Hematol       Date:  2012-12-19

6.  Successful treatment in a case of Propionibacterium acnes-associated sarcoidosis with clarithromycin administration: a case report.

Authors:  Nobuo Takemori; Masaya Nakamura; Masaru Kojima; Yoshinobu Eishi
Journal:  J Med Case Rep       Date:  2014-01-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.